NCT05001555

Brief Summary

Phase IIIb, multicenter, prospective, randomized, double-blind study to evaluate the fixed combination of Desketoprofen / Vitamin B in the management of acute pain in patients with cervical sprain grade I-II of the Quebec scale.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
174

participants targeted

Target at P25-P50 for phase_3

Timeline
Completed

Started Nov 2021

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 29, 2021

Completed
14 days until next milestone

First Posted

Study publicly available on registry

August 12, 2021

Completed
3 months until next milestone

Study Start

First participant enrolled

November 23, 2021

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 24, 2023

Completed
1 day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 25, 2023

Completed
Last Updated

November 13, 2024

Status Verified

November 1, 2024

Enrollment Period

1.4 years

First QC Date

July 29, 2021

Last Update Submit

November 11, 2024

Conditions

Outcome Measures

Primary Outcomes (5)

  • Changes in pain intensity

    Compare changes in pain intensity measured by the visual analog scale (VAS) between treatment groups. The VAS for pain is a straight line of 10 centimeters in which one end means no pain and the other end means the worst pain imaginable.

    Baseline, 3, 5 and 7 days

  • Change in the degree of disability

    Compare the degree of disability due to neck pain measured through the Northwick Park Neck Pain Questionnaire Spanish version between the treatment groups. It includes 9 questions or items (intensity of neck pain, and sleep, pins and needles in the arms at night, duration of symptoms, lifting weights, reading and watching TV, work, social activities and driving). Each of these questions has five possible answers with a score of 0 to 4, from less to greater intensity and severity respectively.

    Baseline, 3, 5 and 7 days

  • Proportion of subjects requiring rescue medication

    Compare the proportion of subjects requiring rescue medication during the study between treatment groups.

    7 days

  • Adverse events frequency

    Compare the proportion of subjects that presented an adverse event between treatment groups.

    7 days

  • Adverse events intensity

    Compare the intensity of adverse events presented during the study, between treatment groups.

    7 days

Study Arms (2)

Group A: Dexketoprofen/Vitamin B (Thiamine mononitrate/Pyridoxine hydrochloride/Cyanocobalamin)

EXPERIMENTAL

Group A: Dexketoprofen/Vitamin B (Thiamine mononitrate/Pyridoxine hydrochloride/Cyanocobalamin), 1 capsule, orally, every 8 hours, for 7 days.

Drug: Dexketoprofen/Vitamin B

Group B: Dexketoprofen

ACTIVE COMPARATOR

Group B: Dexketoprofen, 1 tablet, orally, every 8 hours, for 7 days.

Drug: Dexketoprofen

Interventions

1 capsule containing 25 mg of dexketoprofen / vitamin B (thiamine mononitrate 100 mg, Pyridoxine hydrochloride 50 mg, Cyanocobalamin 0.50 mg), orally, every 8 hours, for 7 days.

Also known as: D/VitB
Group A: Dexketoprofen/Vitamin B (Thiamine mononitrate/Pyridoxine hydrochloride/Cyanocobalamin)

1 tablet of dexketoprofen 25 mg, orally, every 8 hours, for 7 days.

Also known as: D
Group B: Dexketoprofen

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Any sex.
  • That the subject agree to participate in the study and give your written informed consent.
  • Age\> 18 years old at the beginning of the study.
  • Diagnosis of a grade I or Grade II cervical sprain on the Quebec scale of no more than 3 days.
  • Visual Analog Scale (VAS) ≥4 cm.
  • Women of childbearing potential using a contraceptive method (barrier, oral hormonal, injectable, subdermal), menopausal or surgically sterile.

You may not qualify if:

  • Patient in whom the drug is contraindicated for medical reasons.
  • History of allergic reaction to NSAIDs, thiamine, pyridoxine and cyanocobalamin or hypersensitivity to the components of the formula.
  • A significant history of gastrointestinal disorders (for example: Gastric Ulcer, Crohn's Disease, Ulcerative Colitis, etc.)
  • Previous treatment with opioids reported in the medical history.
  • History of inflammatory arthritis (eg rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, gout).
  • History of chronic pain (eg, fibromyalgia), metastasis, and Paget's disease.
  • History of alcohol or drug abuse in the last year according to DSM-V.
  • Clinical and radiological data of cervical sprain grade III or IV of the Quebec scale.
  • History of illness or injury for more than 6 months in the neck or cervical spine
  • Patient with symptoms of spinal cord injury (weakness, incoordination or paralysis in any part of the body, numbness, tingling or loss of sensation in the hands, fingers, feet or toes, etc.)
  • History of severe acute or chronic liver failure.
  • History of moderate to severe renal failure.
  • A significant history of coagulation problems (Von Willembrand, hemophilia, vitamin K deficiency, etc.).
  • At medical discretion, a disease that affects the prognosis and prevents outpatient management, for example, but not restricted to: end-stage cancer, kidney, heart, respiratory or liver failure or mental illness or with scheduled surgical or hospital procedures.
  • History / presence of any disease or condition that, in the opinion of the Investigator, could pose a risk to the patient or confuse the efficacy and safety of the study results.
  • +5 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Laboratorio Silanes, S.A. de C.V.

Mexico City, Mexico City, 11000, Mexico

Location

Related Publications (13)

  • Spitzer WO, Skovron ML, Salmi LR, Cassidy JD, Duranceau J, Suissa S, Zeiss E. Scientific monograph of the Quebec Task Force on Whiplash-Associated Disorders: redefining "whiplash" and its management. Spine (Phila Pa 1976). 1995 Apr 15;20(8 Suppl):1S-73S. No abstract available.

    PMID: 7604354BACKGROUND
  • Rodriquez AA, Barr KP, Burns SP. Whiplash: pathophysiology, diagnosis, treatment, and prognosis. Muscle Nerve. 2004 Jun;29(6):768-81. doi: 10.1002/mus.20060.

    PMID: 15170609BACKGROUND
  • Hartling L, Brison RJ, Ardern C, Pickett W. Prognostic value of the Quebec Classification of Whiplash-Associated Disorders. Spine (Phila Pa 1976). 2001 Jan 1;26(1):36-41. doi: 10.1097/00007632-200101010-00008.

    PMID: 11148643BACKGROUND
  • Bagan JV, Lopez Arranz JS, Valencia E, Santamaria J, Eguidazu I, Horas M, Forns M, Zapata A, Artigas R, Mauleon D. Clinical Comparison of Dexketoprofen Trometamol and Dipyrone in Postoperative Dental Pain. J Clin Pharmacol. 1998 Dec;38(S1):55S-64S. doi: 10.1002/jcph.1998.38.s1.55.

    PMID: 29023870BACKGROUND
  • Ponce-Monter HA, Ortiz MI, Garza-Hernandez AF, Monroy-Maya R, Soto-Rios M, Carrillo-Alarcon L, Reyes-Garcia G, Fernandez-Martinez E. Effect of diclofenac with B vitamins on the treatment of acute pain originated by lower-limb fracture and surgery. Pain Res Treat. 2012;2012:104782. doi: 10.1155/2012/104782. Epub 2011 Oct 31.

    PMID: 22135737BACKGROUND
  • Curatolo M, Sveticic G. Drug combinations in pain treatment: a review of the published evidence and a method for finding the optimal combination. Best Pract Res Clin Anaesthesiol. 2002 Dec;16(4):507-19. doi: 10.1053/bean.2002.0254.

    PMID: 12516888BACKGROUND
  • Levin OS, Moseikin IA. [Vitamin B complex (milgamma) in the treatment of vertebrogenic lumbosacral radiculopathy]. Zh Nevrol Psikhiatr Im S S Korsakova. 2009;109(10):30-5. Russian.

    PMID: 20037567BACKGROUND
  • Kuhlwein A, Meyer HJ, Koehler CO. [Reduced diclofenac administration by B vitamins: results of a randomized double-blind study with reduced daily doses of diclofenac (75 mg diclofenac versus 75 mg diclofenac plus B vitamins) in acute lumbar vertebral syndromes]. Klin Wochenschr. 1990 Jan 19;68(2):107-15. doi: 10.1007/BF01646857. German.

    PMID: 2138683BACKGROUND
  • Perez-Flores E, Medina-Santillan R, Reyes-Garcia G, Mateos-Garcia E. Combination of diclofenac plus B vitamins in acute pain after tonsillectomy: a pilot study. Proc West Pharmacol Soc. 2003;46:88-90. No abstract available.

    PMID: 14699896BACKGROUND
  • Mibielli MA, Geller M, Cohen JC, Goldberg SG, Cohen MT, Nunes CP, Oliveira LB, da Fonseca AS. Diclofenac plus B vitamins versus diclofenac monotherapy in lumbago: the DOLOR study. Curr Med Res Opin. 2009 Nov;25(11):2589-99. doi: 10.3111/13696990903246911.

    PMID: 19731994BACKGROUND
  • Gonzalez T, Balsa A, Sainz de Murieta J, Zamorano E, Gonzalez I, Martin-Mola E. Spanish version of the Northwick Park Neck Pain Questionnaire: reliability and validity. Clin Exp Rheumatol. 2001 Jan-Feb;19(1):41-6.

    PMID: 11247324BACKGROUND
  • Gaskell H, Derry S, Wiffen PJ, Moore RA. Single dose oral ketoprofen or dexketoprofen for acute postoperative pain in adults. Cochrane Database Syst Rev. 2017 May 25;5(5):CD007355. doi: 10.1002/14651858.CD007355.pub3.

    PMID: 28540716BACKGROUND
  • Delgado-Garcia P, Alcocer-Herrera JB, Urenda-Quezada A, Alonso-Martinez MD, Bautista-Mendoza MA, Romero-Antonio Y, Mora-Villalobos JC, Sander-Padilla JG, Rios-Brito KF, Rodriguez-Vazquez IC, Gonzalez-Canudas J. A Randomized Control Trial of Dexketoprofen/Vitamin B (Thiamine, Pyridoxine and Cyanocobalamin) Fixed-Dose Combination in Post-Traumatic Grade I-II Cervical Sprains. Clin Drug Investig. 2024 Jun;44(6):413-424. doi: 10.1007/s40261-024-01370-2. Epub 2024 Jun 6.

MeSH Terms

Interventions

dexketoprofen trometamolFolic AcidFumigant 93

Intervention Hierarchy (Ancestors)

PterinsPteridinesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic Compounds

Study Officials

  • Pamela Delgado García, M.D

    IMACEN S.A. de C.V.,

    PRINCIPAL INVESTIGATOR
  • Adelfia Urenda Quezada, M.D

    Mediadvance Clinical S.A.P.I. de C.V.

    PRINCIPAL INVESTIGATOR
  • Ma. Dolores Alonso Martínez, M.D

    CICMEX Centro de Investigación Clínica de México

    PRINCIPAL INVESTIGATOR
  • Juan B Alcocer Herrera, M.D

    INBIOMEDyC Querétaro

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 29, 2021

First Posted

August 12, 2021

Study Start

November 23, 2021

Primary Completion

April 24, 2023

Study Completion

April 25, 2023

Last Updated

November 13, 2024

Record last verified: 2024-11

Data Sharing

IPD Sharing
Will not share

Locations